IMG-EN-AS-61036-05-01.jpg
Peptides

CEF Control Peptide Pool - 16 mg

$1,604.00
Check your price
  • Cat.Number : AS-61036-05
  • Availability :
    In production

Alternative choices

Quantity

Add to wishlist Bulk Quote

The CEF Control Peptide Pool is a group of 32 peptides, 8-12 amino acids in length, with sequences derived from the human Cytomegalovirus, Epstein-Barr Virus and Influenza Virus.This product contains 0.5 mg of the 32 CEF peptides for a total of 16 mg in one vial. Used in the stimulation of IFNg release from CD8+ T cells in individuals with defined HLA types, these epitopes are useful in applications such as ELISPOT, intracellular cytokine and CTL assays.

Specifications

Modification
Conjugation
  • Unconjugated
Quantity & Purity
Purity
  • Peak Area by HPLC ≥95%
Storage & stability
Form
  • Lyophilized
Storage Conditions
  • - 20 °C
Activity
Application
Biomarker Target
Research Area
Sub-category Research Area
Usage
  • Research use
Source
Source / Species
  • CMV, EBV, Influenza

Downloads

You may also be interested in the following product(s)

IMG-EN-AS-62339-01.jpg

Cytomegalovirus (CMV) Control Peptide Pool - 1.25 mg

Cat.Number : AS-62339
$228.00 Excl. Tax
IMG-EN-AS-62341-01.jpg

Epstein-Barr Virus (EBV) Control Peptide Pool - 3.75 mg

Cat.Number : AS-62341
$641.00 Excl. Tax
IMG-EN-AS-62340-01.jpg

Influenza Virus Control Peptide Pool - 3 mg

Cat.Number : AS-62340
$523.00 Excl. Tax

Citations

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.

J Hematol Oncol . 2017 Apr 07 ; 10(1) 82 | DOI : 10.1186/s13045-017-0459-2.

  • S. Mehrotra

Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.

PLoS Pathog . 2017 Feb 24 ; 13(2) e1006232 | DOI : 10.1371/journal.ppat.1006232.

  • N. Bhattarai

Cryopreservation of Human Mucosal Leukocytes.

PLoS One . 2016 May 27 ; 11(5) e0156293 | DOI : 10.1371/journal.pone.0156293.

  • SM. Hughes

Change in CD3ζ-chain expression is an independent predictor of disease status in head and neck cancer patients.

Int J Cancer . 2016 Mar 08 ; 139(1) 122 | DOI : 10.1002/ijc.30046.

  • D. Upreti

Sprouty-2 regulates HIV-specific T cell polyfunctionality.

J Clin Invest . 2014 Jan 01 ; 124(1) 198 | DOI : 10.1172/JC170510.

  • YL. Chiu

Memory phenotypes of HIV-specific CD8+ T cell responses are independent of functional activity as defined by cytokine output.

Open J Immunol . 2014 Sep 01 ; 4(3) 83 | DOI : 10.4236/oji.2014.43012.

  • ME. Richmond

Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes.

PloS One . 2014 Sep 11 ; 9(9) e106241 | DOI : 10.1371/journal.pone.0106241.

  • M. Sedegah

Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk.

J Immunol . 2014 Jul 30 ; 93(5) 2297 | DOI : 10.4049/​jimmunol.1400489.

  • K. Sehgal

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

Clin Cancer Res . 2013 Dec 09 ; 20(5) 1125 | DOI : 10.1158/1078-0432.CCR-13-2147

  • DA. Wick

T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.

Breast Cancer Res Treatment . 2013 Jun 08 ; 139(3) 657 | DOI : 10.1007/s10549-013-2577-z

  • DL. Cecil

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.

Oncoimmunol . 2013 Jun 10 ; 2(7) e25205 | DOI : 10.4161/onci.25205.

  • KM. Dhodapkar

Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant.

Vaccine . 2013 May 22 ; 31(32) 3257 | DOI : 10.1016/j.vaccine.2013.05.028

  • EH. Eypper

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).

Malaria J . 2013 Jun 05 ; 12 185 | DOI : 10.1186/1475-2875-12-185

  • M. Sedegah

T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO.

J Viral Hepatitis . 2012 Apr 19 ; 19(12) 872 | DOI : 10.1111/j.1365-2893.2012.01611.x.

  • F. Bayard

A Poxvirus vaccine is safe, induces T-Cell responses, and decreases viral load in patients with chronic Hepatitis C.

Gastroenterol . 2011 Jun 13 ; 141(3) 890 | DOI : 10.1053/j.gastro.2011.06.009

  • F. Habersetzer

Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.

Cellular Immunol . 2011 Apr 23 ; 270(1) 62 | DOI : 10.1016/j.cellimm.2011.04.005

  • M. Matijevic

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.

J Transl Med . 2011 Mar 08 ; 9 26 | DOI : 10.1186/1479-5876-9-26

  • WC. Olson

An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.

J Immunol Methods . 2010 Jul 15 ; 360(1-2) 149 | DOI : 10.1016/j.jim.2010.07.003

  • JS. Nielsen

Measuring T-cell immunity in HIV vaccine clinical trials: PBMC and ELISPOT assay proficiency concordance in laboratories from 3 continents.

Clin Vaccine Immunol . 2008 Dec 17 ; | DOI : 10.1128/CVI.00326-08.

  • M. Boaz

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.

J Exp Med . 2008 Nov 10 ; 205(12) 2763 | DOI : 10.1084/jem.20081398.

  • RB. Jones

Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.

J Immunol Methods . 2007 Feb 28 ; 322(1-2) 57 | DOI : 10.1016/j.jim.2007.02.003

  • M. Bull

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

J Immunol Methods . 2006 Aug 15 ; 315(1-2) 121 | DOI : 10.1016/j.jim.2006.07.015

  • Z. Moodie

References

Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function.

J Virol . 2010 Nov 17 ; 85(3) 1275 | DOI : 10.1128/JVI.01707-10.

  • ME. Richmond

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

J Immunol Methods . 2002 Feb 01 ; 260(1-2) 157 | DOI : https://doi.org/10.1016/S0022-1759(01)00535-X

  • JR. Currier
  • et al

Design and Validation of an Enzyme-Linked Immunospot Assay for Use in Clinical Trials of Candidate HIV Vaccines

AIDS Res Hum Retroviruses . 2002 Jun 01 ; 18(9) 611 | DOI : https://doi.org/10.1089/088922202760019301

  • M. Mwau
  • et al